KGX103 / KangaBio - LARVOL DELTA

KGX-103 exerts antitumoral activity in vivo in A375 melanoma model (Bioworld) - "Both IL-15 and IL-2 are good options for cancer therapy, but IL-15 is considered superior due to lower vascular endothelial toxicity, stronger ability to expand natural killer and CD8+ T cells and weaker stimulation of T regulatory cells, but it has a short half-life and exerts severe adverse effects."

Preclinical • Melanoma

KGX103, a conditionally active prodrug of PD-1-targeting IL-15 induces antitumor activity by preferentially activating PD-1+ intratumoral T cells in cis (AACR 2025) - "Compared to the vehicle group, KGX103 demonstrated its antitumor efficacy and safety as evidenced by significant tumor growth inhibition while no obvious body weight change during the dosing period. The pilot toxic study to evaluate the safety and toxicokinetics of KGX103 is ongoing in Cynomolgus monkeys."

IO biomarker • Oncology • CD8 • IL15 • IL2